StockData

Fulcrum Therapeutics vs Spero Therapeutics

FULC and SPRO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How FULC and SPRO compare

Fulcrum Therapeutics is the larger company, worth 4.8 times as much as Spero Therapeutics ($285M against $59.4M).

Spero Therapeutics scores higher on the StockData Score (11 against 8 for Fulcrum Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricFULCSPRO
Size and price
Market cap$285M$59.4M
Share price$3.74$1.02
Change, 1 year−51.2%−59.2%
Change, 5 years−78.2%−93.8%
Beta (5Y)1.571.13
Employees5525
StockData Score
Total score811 (better)
Valuation score13 (better)
Growth score00
Performance score13 (better)
Health score6 (better)5
Dividend score00
Valuation
P/E–25.5×
P/S–1.3×
P/B0.9× (better)1.3×
EV/EBITDA–1.4×
FCF yield−23.2%–
Fair value–$1.72
Margin of safety–40.7%
Growth
Revenue growth (TTM)–−3.3%
Revenue growth, 5Y average–48.2%
Profitability
Operating margin–12.8%
Net margin–15.7%
Return on equity−32.4%19.2% (better)
Return on invested capital−35.0%–
Financial health
Debt / equity0.000.00
Current ratio31.35 (better)6.12
Altman Z-score10.33 (better)−6.00
Piotroski F-score35 (better)
Dividends and buybacks
Buyback yield−1.5%–
Shareholder yield−1.5%0.00% (better)
Ownership
Held by institutions112%36.9%
Held by insiders34.7%24.6%
Insider net buying, 12 months−$57.5M−$499K (better)
Short interest, % of float12.9%1.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.